Shattuck Labs' stock tumbles after Phase 1 SL-325 data release despite analyst upgrades, a Buy consensus rating, and progress in IBD treatment.

Shattuck Labs' stock tumbles after Phase 1 SL-325 data release despite analyst upgrades, a Buy consensus rating, and progress in IBD treatment.

Shattuck Labs ($STTK) shares fluctuate after pricing a $75M public offering at $4.00/share. Get the latest stock updates here.